Company:  OREXIGEN THERAPEUTICS, IN ... (OREX)
Form Type:  10-Q
Filing Date:  11/9/2007 
CIK:  0001382911 
Address:  3344 N. TORREY PINES CT.
SUITE 200
 
City, State, Zip:  LA JOLLA, California 92037 
Telephone:  (858) 875-8600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$5.53  
Change: 
-0.01 (-0.18%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$617.21M
Description of Business
Orexigen� Therapeutics, Inc. (�Orexigen�, �we�, �our� and �us�) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Our product candidates are NB32 (formerly referred to as Contrave�), which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic�, which has completed Phase II clinical trials. Each of these product candidates is a combination of generic drug components, each of which has already received regulatory approval for other indications and been commercialized in the United States and in a majority of the member countries of the European Union. NB32 is a combination of two well-established drugs, bupropion and naltrexone, each in a sustained release, or SR, formulation. Bupropion is a widely prescribed antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction.
Register for a Free Trial and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO UNAUDITED FINANCIAL STATEMENTS
          BALANCE SHEET
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF ...
      ITEM 3. DEFAULTS UPON SENIOR SECURITIES
      ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
      ITEM 5. OTHER INFORMATION
      ITEM 6. EXHIBITS
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,